Transcriptional Patterns in Peritoneal Tissue of Encapsulating Peritoneal Sclerosis, a Complication of Chronic Peritoneal Dialysis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Reimold, Fabian R ^a,b   Braun, Niko ^b,c   Zsengellér, Zsuzsanna K ^a   Stillman, Isaac E ^a   Karumanchi, S Ananth ^a   Toka, Hakan R ^a,d   Latus, Joerg ^b,c   Fritz, Peter ^b   Biegger, Dagmar ^b,e   Segerer, Stephan ^f   Alscher, M Dominik ^b,c   Bhasin, Manoj K ^a   Alper, Seth L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c Institute of Digital Medicine   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; CHEMOKINE; COLLAGEN TYPE 1; FIBRONECTIN; FIBRONECTIN 1; GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; MESSENGER RNA; RETINOL BINDING PROTEIN 4; SULFATASE; SULFATASE 1; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOCALIZATION; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UREMIA;

AGED; COLLAGEN TYPE I; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; LEPTIN; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; RETINOL-BINDING PROTEINS, PLASMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84873931247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056389     Document Type: Article

References (82)

1. Lameire N, Van Biesen W, (2010) Epidemiology of peritoneal dialysis: a story of believers and nonbelievers. Nat Rev Nephrol 6: 75-82.
2. Braun N, Alscher MD, Kimmel M, Amann K, Buttner M, (2011) Encapsulating peritoneal sclerosis- an overview. Nephrol Ther 7: 162-171.
3. Kawanishi H, Shintaku S, Moriishi M, Dohi K, Tsuchiya S, (2011) Seventeen years' experience of surgical options for encapsulating peritoneal sclerosis. Adv Perit Dial 27: 53-58.
4. Ulmer C, Braun N, Rieber F, Latus J, Hirschburger S, et al. (2012) Efficacy and morbidity of surgical therapy in late-stage encapsulating peritoneal sclerosis. Surgery.
5. Latus J, Ulmer C, Fritz P, Rettenmaier B, Biegger D, et al. (2012) Encapsulating peritoneal sclerosis: a rare, serious but potentially curable complication of peritoneal dialysis-experience of a referral centre in Germany. Nephrol Dial Transplant.
6. Da Luz MM, Barral SM, Barral CM, Bechara Cde S, Lacerda-Filho A, (2011) Idiopathic encapsulating peritonitis: report of two cases. Surg Today 41: 1644-1648.
7. Koak Y, Gertner D, Forbes A, Ribeiro BF, (2008) Idiopathic sclerosing peritonitis. Eur J Gastroenterol Hepatol 20: 148-150.
8. Minutolo V, Gagliano G, Angirillo G, Minutolo O, Morello A, et al. (2008) Intestinal obstruction due to idiopathic sclerosing encapsulating peritonitis. Clinical report and review of literature. G Chir 29: 173-176.
9. Johnson DW, Cho Y, Livingston BE, Hawley CM, McDonald SP, et al. (2010) Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 77: 904-912.
10. Brown MC, Simpson K, Kerssens JJ, Mactier RA, (2009) Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 4: 1222-1229.
11. Toyohara T, Ubara Y, Higa Y, Suwabe T, Hoshino J, et al. (2011) Prognosis of patients on continuous ambulatory peritoneal dialysis (CAPD) for over 10 years. Intern Med 50: 2519-2523.
12. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, et al. (2004) Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 44: 729-737.
13. Kawanishi H, Moriishi M, (2005) Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 25 Suppl 4: S14-18.
14. Korte MR, Habib SM, Lingsma H, Weimar W, Betjes MG, (2011) Posttransplantation encapsulating peritoneal sclerosis contributes significantly to mortality after kidney transplantation. Am J Transplant 11: 599-605.
15. Braun N, Alscher DM, Schwenger V, Amann K, Büttner M, (2010) Deutsches Peritonealdialyseregister (DPR). Der Nephrologe 5: 531-534.
16. Nakamura S, Niwa T, (2004) Advanced glycation end-products and peritoneal sclerosis. Semin Nephrol 24: 502-505.
17. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, et al. (2006) Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 17: 199-207.
18. Alscher DM, Braun N, Biegger D, Fritz P, (2007) Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 49: 452-461.
19. Aoki S, Ikeda S, Takezawa T, Kishi T, Makino J, et al. (2011) Prolonged effect of fluid flow stress on the proliferative activity of mesothelial cells after abrupt discontinuation of fluid streaming. Biochem Biophys Res Commun 416: 391-396.
20. Aoki S, Makino J, Nagashima A, Takezawa T, Nomoto N, et al. (2011) Fluid flow stress affects peritoneal cell kinetics: possible pathogenesis of peritoneal fibrosis. Perit Dial Int 31: 466-476.
21. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME, (2009) Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract 111: c149-154; discussion c154.
22. Braun N, Alscher DM, Fritz P, Edenhofer I, Kimmel M, et al. (2011) Podoplanin-positive cells are a hallmark of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 26: 1033-1041.
23. Vlijm A, Stoker J, Bipat S, Spijkerboer AM, Phoa SS, et al. (2009) Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 29: 517-522.
24. Braun N, Fritz P, Ulmer C, Kimmel M, Biegger D, et al. (2012) The Definition of Histological Criteria for Encapsulating Peritoneal Sclerosis - A Standardized Approach [Abstract]. PLoS One In press.
25. Nakamoto H, (2005) Encapsulating peritoneal sclerosis-a clinician's approach to diagnosis and medical treatment. Perit Dial Int 25 Suppl 4: S30-38.
26. Kawanishi H, Harada Y, Noriyuki T, Kawai T, Takahashi S, et al. (2001) Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 17: 200-204.
27. Yamamoto H, Nakayama M, yamamoto R, Otsuka Y, Takahashi H, et al. (2002) Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. Adv Perit Dial 18: 135-138.
28. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R, (2005) Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 25: 285-287.
29. Fieren MW, Betjes MG, Korte MR, Boer WH, (2007) Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 27: 619-624.
30. Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, et al. (2011) Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 26: 691-697.
31. Braun N, Fritz P, Biegger D, Kimmel M, Reimold F, et al. (2011) Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum-implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. Perit Dial Int 31: 291-300.
32. Bhasin M, Yuan L, Keskin DB, Otu HH, Libermann TA, et al. (2010) Bioinformatic identification and characterization of human endothelial cell-restricted genes. BMC Genomics 11: 342.
33. Nakamoto H, Imai H, Fukushima R, Ishida Y, Yamanouchi Y, et al. (2008) Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 28 Suppl 3: S83-87.
34. Kawanishi H, Ide K, Yamashita M, Shimomura M, Moriishi M, et al. (2008) Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis. Adv Perit Dial 24: 51-55.
35. Park SH, Kim YL, Lindholm B, (2008) Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment. Perit Dial Int 28 Suppl 5: S21-28.
36. Le SJ, Gongora M, Zhang B, Grimmond S, Campbell GR, et al. (2010) Gene expression profile of the fibrotic response in the peritoneal cavity. Differentiation 79: 232-243.
37. Imai T, Hirahara I, Morishita Y, Onishi A, Inoue M, et al. (2011) DNA microarray analysis of the epithelial-mesenchymal transition of mesothelial cells in a rat model of peritoneal dialysis. Adv Perit Dial 27: 11-15.
38. Yokoi H, Kasahara M, Mori K, Ogawa Y, Kuwabara T, et al. (2012) Pleiotrophin triggers inflammation and increased peritoneal permeability leading to peritoneal fibrosis. Kidney Int 81: 160-169.
39. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, et al. (2005) Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 16: 425-436.
40. Honda K, Nitta K, Horita S, Tsukada M, Itabashi M, et al. (2003) Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 19: 169-175.
41. Kauffmann A, Gentleman R, Huber W, (2009) arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics 25: 415-416.
42. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
43. Wang C, Rao N, Wang Y, (2007) [Principal component analysis for exploring gene expression patterns]. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 24: 736-741.
44. Yeung KY, Ruzzo WL, (2001) Principal component analysis for clustering gene expression data. Bioinformatics 17: 763-774.
45. Li C, Wong WH, (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proceedings of the National Academy of Sciences of the United States of America 98: 31-36.
46. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, et al. (1999) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A 96: 2907-2912.
47. Ayuzawa N, Ishibashi Y, Takazawa Y, Kume H, Fujita T, (2012) Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan. Perit Dial Int 32: 159-167.
48. Garcia-Lopez E, Lindholm B, Davies S, (2012) An update on peritoneal dialysis solutions. Nat Rev Nephrol 8: 224-233.
49. Baroni G, Schuinski A, de Moraes TP, Meyer F, Pecoits-Filho R, (2012) Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis. Mediators Inflamm 2012: 912595.
50. Mizuno M, Ito Y, Mizuno T, Harris CL, Suzuki Y, et al. (2012) Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats. Am J Physiol Renal Physiol 302: F1245-1251.
51. Mizuno T, Mizuno M, Morgan BP, Noda Y, Yamada K, et al. (2011) Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrol Dial Transplant 26: 1821-1830.
52. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, et al. (2011) Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332: 1284-1288.
53. Fieren MW, (2012) The local inflammatory responses to infection of the peritoneal cavity in humans: their regulation by cytokines, macrophages, and other leukocytes. Mediators Inflamm 2012: 976241.
54. Wang W, He B, Shi W, Liang X, Ma J, et al. (2012) Deletion of scavenger receptor A protects mice from progressive nephropathy independent of lipid control during diet-induced hyperlipidemia. Kidney Int 81: 1002-1014.
55. Yerlikaya FH, Mehmetoglu I, Kurban S, Tonbul Z, (2011) Plasma fatty acid composition in continuous ambulatory peritoneal dialysis patients: an increased omega-6/omega-3 ratio and deficiency of essential fatty acids. Ren Fail 33: 819-823.
56. Mehrotra R, Duong U, Jiwakanon S, Kovesdy CP, Moran J, et al. (2011) Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis. Am J Kidney Dis 58: 418-428.
57. Garibotto G, Sofia A, Saffioti S, Bonanni A, Mannucci I, et al. (2012) Effects of peritoneal dialysis on protein metabolism. Nutr Metab Cardiovasc Dis.
58. Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, et al. (1997) Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J Clin Endocrinol Metab 82: 561-565.
59. Lai KN, Lam MF, Leung JC, Chan LY, Lam CW, et al. (2012) A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Perit Dial Int 32: 280-291.
60. Wojcik K, Stompor T, Krzanowski M, Miarka P, Zdzienicka A, et al. (2007) The relationships between activation of non-specific inflammatory process and malnutrition in patients on peritoneal dialysis. Med Pregl 60 Suppl 2: 114-116.
61. Matsubara K, Kiyomoto H, Moriwaki K, Hara T, Kondo N, et al. (2004) Leptin kinetics during peritoneal dialysis in acutely uraemic rats. Nephrology (Carlton) 9: 256-261.
62. Teta D, Tedjani A, Burnier M, Bevington A, Brown J, et al. (2005) Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes. Nephrol Dial Transplant 20: 1329-1335.
63. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, et al. (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354: 2552-2563.
64. Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, et al. (2012) Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics. Oncol Rep 27: 318-324.
65. Sagara A, Sakai N, Shinozaki Y, Kitajima S, Toyama T, et al. (2011) Histone Acetyltransferase Activity Is Involved in the Pathogenesis of Experimental Peritoneal Fibrosis [Abstract]. J Am Soc Nephrol pp. 36A.
66. Wang HR, Chen DL, Zhao M, Shu SW, Xiong SX, et al. (2012) C-reactive protein induces interleukin-6 and thrombospondin-1 protein and mRNA expression through activation of nuclear factor-kB in HK-2 cells. Kidney Blood Press Res 35: 211-219.
67. Sweetwyne MT, Murphy-Ullrich JE, (2012) Thrombospondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms. Matrix Biol 31: 178-186.
68. Bige N, Shweke N, Benhassine S, Jouanneau C, Vandermeersch S, et al. (2012) Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int 81: 1226-1238.
69. Grinnell F, (1984) Fibronectin and wound healing. J Cell Biochem 26: 107-116.
70. Valenick LV, Hsia HC, Schwarzbauer JE, (2005) Fibronectin fragmentation promotes alpha4beta1 integrin-mediated contraction of a fibrin-fibronectin provisional matrix. Exp Cell Res 309: 48-55.
71. Muro AF, Moretti FA, Moore BB, Yan M, Atrasz RG, et al. (2008) An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177: 638-645.
72. Leask A, Abraham DJ, (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
73. Van Vliet A, Baelde HJ, Vleming LJ, de Heer E, Bruijn JA, (2001) Distribution of fibronectin isoforms in human renal disease. J Pathol 193: 256-262.
74. Doerner AM, Zuraw BL, (2009) TGF-beta1 induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells is enhanced by IL-1beta but not abrogated by corticosteroids. Respir Res 10: 100.
75. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, et al. (2003) Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 348: 403-413.
76. Han M, Liu M, Wang Y, Chen X, Xu J, et al. (2012) Antagonism of miR-21 Reverses Epithelial-Mesenchymal Transition and Cancer Stem Cell Phenotype through AKT/ERK1/2 Inactivation by Targeting PTEN. PLoS One 7: e39520.
77. Margetts PJ, (2012) Twist: a new player in the epithelial-mesenchymal transition of the peritoneal mesothelial cells. Nephrol Dial Transplant.
78. El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, et al. (2012) Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A.
79. Coral K, Madhavan J, Pukhraj R, Angayarkanni N, (2012) High Glucose Induced Differential Expression of Lysyl Oxidase and Its Isoform in ARPE-19 Cells. Curr Eye Res.
80. Herranz N, Dave N, Millanes-Romero A, Morey L, Diaz VM, et al. (2012) Lysyl oxidase-like 2 deaminates lysine 4 in histone H3. Mol Cell 46: 369-376.
81. Lugassy J, Zaffryar-Eilot S, Soueid S, Mordoviz A, Smith V, et al. (2012) The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation. J Biol Chem 287: 3541-3549.
82. Guo H, Leung JC, Lam MF, Chan LY, Tsang AW, et al. (2007) Smad7 transgene attenuates peritoneal fibrosis in uremic rats treated with peritoneal dialysis. J Am Soc Nephrol 18: 2689-2703.